SWISS BIOTECH SUCCESS STORY

Zug

Biogen

The origins of Biogen are in Geneva, Switzerland, where the company was founded in 1978

Biogen is the world's third largest biotechnology company with 7,000 employees in 30 countries

From its foundation through to its recent return to Switzerland with a CHF 1.5bn investment in a new plant, the company's successes bear to show many Swiss traits

The next-generation biologic manufacturing facility in Luterbach will create up to 600 new jobs

SWISS MARKERS AT BIOGEN
Founded in Geneva 1978

Established international headquarters in Zug in 2004

Planned opening of major production site in Luterbach in 2019

KNOWLEDGE
Innovative scientific research with the goal of defeating devastating neurological diseases

INDICATIONS
Therapies for serious medical conditions with few or no treatment options: multiple sclerosis, spinal muscular atrophy, biosimilars of advanced biologics

IN-LICENSING AGREEMENTS & PIPELINE
Targeting devastating neurological diseases such as Multiple Sclerosis (MS), Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and Progressive Supranuclear Palsy (PSP)

Various compounds licensed from, and developed in collaboration with, Neurimmune of Schlieren

neurimmune
Promind antibody therapeutics

SUCCESS CATEGORIES

- ★ Completed achievement with lasting impact
- ★ Scientific breakthrough
- ★ New technology
- ★ Strong impact on society
- ★ Product approval and sustainable revenues

- ★ Involvement of one or more Swiss citizens
- ★ Swiss-based company/institution
- ★ Creation of jobs in Switzerland
- ★ Enabler for the biotech industry
- ★ Swissness: Think global, made in Switzerland

SWISS BIOTECH™

Organized by

Swiss Biotech Association